A Preview of Potentially Historic FDA Approvals for 2023
The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…
The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…
As recently reported by Forbes, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab) for Alzheimer’s disease earlier this week. Leqembi is a humanized monoclonal antibody that targets…
The FDA advisory panel which is composed of specialists who advise the FDA on brain medications, recently voted 6-0 in agreement on that the new drug, Leqembi, was effective…
A Business Wire Press Release on April 26, 2023, announced positive interim clinical data on an investigational RNAi therapeutic. Alnylam Pharmaceuticals and its partner Regeneron Pharmaceuticals heralded interim results…
The failure rate of drug development for Alzheimer’s is 99 percent according to a recent study. Since 1984 scientists have concentrated on developing treatments to prevent the formation of…
Over the years, there has been tons of research exploring the exact causes of Alzheimer’s disease. Researchers have hypothesized that a combination of lifestyle, environmental, and genetic factors could play…
According to a story from myscience.org, neurodegenerative diseases, such as amyotrophic lateral sclerosis, are diseases that progressively worsen over time. However, progression in this disease is not consistent across all…
For more than two decades, deep brain stimulation (DBS) has been a therapeutic option for people living with Parkinson’s disease. Through regulating brain activity, DBS helps to relieve symptoms and…
From September to January each year, our home transforms; each Sunday, my boyfriend and I meticulously set up our living room, make snacks, and spend the day watching football on…
Researchers have known about EGCG for decades. It is a plant compound called catechin found in green tea that may prevent disease and protect cells from damage. According to…
Verge Genomics, based in San Francisco is one of a series of biotechs that have entered into a new era using AI in drug discovery. The company is backed by…
Oxytocin has been deemed the "love drug" or "love hormone." This hormone, which controls aspects of behavior and reproduction, is often released when we're in love or in physical…
Aduhelm was recently approved by the FDA for the treatment of Alzheimer’s disease (AD). The FDA approval, the first in the history of the disease, was based on the drug’s…
A New Theory The Week reports that scientists at the Krembil Brain Institute in Toronto are working on a new theory about the origins of Alzheimer's disease. The Toronto…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Happy Monday! This week, we have details on a method for detecting Alzheimer's 17 years in advance, the story of a teen living with Usher syndrome, and a possible breakthrough…
A recent article in SciTechDaily explains that the many failures of newly created Alzheimer’s drugs are the result of clinical plaque tests that do not identify the disease in its…
The gut-brain axis has recently been mentioned in connection with various disorders. According to an article in SciTechDaily, a study at ECU’s Centre for Precision Health confirms a genetic…
Currently, there are upwards of six million people in the United States alone living with Alzheimer’s disease. As some researchers work to determine the exact cause of this neurodegenerative…
Pursuing an Alzheimer’s disease diagnosis can not only be costly, but time-consuming. It may take numerous neuropsychological examinations, alongside other testing and analysis, to confirm this diagnosis. The issue is…
The number of Alzheimer’s disease diagnoses has been rising rapidly over the last few decades. Today, an estimated 6.5 million Americans alone are living with this disease. Yet there…
The study was intended to recruit 6,000 Alzheimer's patients, but even after recruiting had proceeded for seven months, just 29 patients were enrolled. As a result, the trial was cancelled,…
The Irish Times recently featured a book by Dr. Karl Herrup about “How Not to Study a Disease." Dr. Herrup is clear that he opposes the theory that the amyloid…
Alzheimer’s disease is the primary cause of the progressive decline of cognitive function in the elderly. It is characterized by underlying complications in the central nervous system (CNS). To date,…
According to information from the National Institute of Health, one in nine elderly people in the U.S. will be affected by Alzheimer’s disease (AD). A recent article in the Globe Newswire…